👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Cluster of drug-resistant mpox identified in five states, US officials report

Published 10/10/2024, 01:05 PM
Updated 10/10/2024, 01:10 PM
© Reuters. FILE PHOTO: A test tube labelled "Mpox virus positive" is held in this illustration taken August 20, 2024. REUTERS/Dado Ruvic/Illustration/File Photo

By Julie Steenhuysen

CHICAGO (Reuters) - U.S. health officials have identified a cluster of cases caused by an mpox variant that are resistant to Siga Technologies' antiviral tecovirimat, branded as TPOXX, in five U.S. states, federal and state researchers reported on Thursday.

The cases involved a total of 18 individuals infected with clade II mpox between Oct. 6, 2023, and Feb. 15, 2024, who had never taken the treatment before, according to the report published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

Clade II mpox cases, which are endemic to West Africa, sparked a global outbreak in 2022 that prompted the World Health Organization to declare a public health emergency, and cases continue to spread at low levels in some countries.

The drug-resistant mpox cases follow an initial, unrelated cluster reported in California in late 2022-early 2023, and are the first involving multiple states, according to the report.

Health officials said the latest cases are likely to have been underestimated because not all cases of mpox undergo genetic sequencing to determine the variant causing the infection.

Study authors said routine surveillance is needed to monitor for the emergence of drug resistance to safeguard the effectiveness of TPOXX, one of the few treatments approved for treatment of mpox.

CDC officials advised doctors to closely follow the protocol for TPOXX use, ensure that patients take the drug properly and stress that they can still spread the virus while taking the drug. The findings also underscore the need for additional mpox treatments, the study authors said.

The clade II strain is separate from the ongoing outbreak in Africa of a new variant called clade Ib, which prompted the WHO to declare a second public health emergency in August.

© Reuters. FILE PHOTO: A test tube labelled

A U.S. government-backed study evaluating the use of TPOXX in clade Ib cases released in August showed the treatment was not effective at helping patients recover more quickly than a dummy treatment.

Mpox, formerly known as monkeypox, is a viral infection that causes flu-like symptoms and pus-filled lesions. Although usually mild, the virus can be deadly in some individuals with weakened immune symptoms. Mpox is transmitted through close physical contact, including sexual contact.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.